SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version: 5.0
Revision Date: 23.03.2020
SDS Number: 1209999-00010
Date of last issue: 13.09.2019
Date of first issue: 10.01.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 91-105 Harpin Street
Bendigo 3550, Victoria Australia
Telephone: 908-740-4000
Emergency telephone number: 1 800 033 461
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 1 800 817 414

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral): Category 4
Acute toxicity (Inhalation): Category 4
Skin corrosion/irritation: Category 2
Serious eye damage/eye irritation: Category 2A
Reproductive toxicity: Category 1B
Specific target organ toxicity - single exposure (Oral): Category 2 (Central nervous system)
Specific target organ toxicity - single exposure: Category 3
Specific target organ toxicity - repeated exposure: Category 2 (Central nervous system)

GHS label elements
Hazard pictograms:
Signal word: Danger
Hazard statements : H302 + H332 Harmful if swallowed or if inhaled.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ eye protection/ face protection.
P281 Use personal protective equipment as required.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/physician if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/attention.
P332 + P313 If skin irritation occurs: Get medical advice/attention.
P337 + P313 If eye irritation persists: Get medical advice/attention.
P362 Take off contaminated clothing and wash before reuse.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.
SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed or if inhaled. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Specific hazards during firefighting:
- Exposure to combustion products may be a hazard to health.
- Hazardous combustion products:
  - Carbon oxides
  - Nitrogen oxides (NOx)

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Hazchem Code:
- •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe vapours or spray mist.
- Do not swallow.
- Do not get in eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-
Assessment
Keep container tightly closed.
Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage
Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.

Materials to avoid
Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn oil</td>
<td>8001-30-7</td>
<td>TWA (Mist)</td>
<td>10 mg/m³</td>
<td>AU OEL</td>
</tr>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>TWA</td>
<td>25 ppm 103 mg/m³</td>
<td>AU OEL</td>
</tr>
</tbody>
</table>

Further information: Skin absorption

|                                           | STEL     | 75 ppm 309 mg/m³              | AU OEL                                         |

Further information: Skin absorption

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin

|                                           | Wipe limit | 0.5 mg/100 cm²                | Internal                                       |

Abamectin (combination of avermectin B1a and avermectin B1b) | 71751-41-2 | TWA                           | 30 µg/m³ (OEB 3)                              | Internal |

|                                           | Wipe limit | 300 µg/100 cm²                | Internal                                       |

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>(dl)-a-Tocopheryl acetate</td>
<td>7695-91-2</td>
<td>TWA</td>
<td>5000 ug/m³ (OEB 1)</td>
</tr>
</tbody>
</table>

Biological occupational exposure limits
Ivermectin / Abamectin Liquid Formulation

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type

Combined particulates and organic vapour type

Hand protection

Material

Chemical-resistant gloves

Remarks

Consider double gloving.

Eye protection

Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

liquid

Colour

light yellow

Odour

characteristic

Odour Threshold

No data available

pH

Not applicable

Melting point/freezing point

No data available
Initial boiling point and boiling range: No data available
Flash point: > 100 °C
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: 0.91 - 1.00 mg/l
Solubility(ies)
  Water solubility: insoluble
Partition coefficient: n-octanol/water: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
  Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
SECTIONS 11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation, Skin contact, Ingestion, Eye contact

Acute toxicity: Harmful if swallowed or if inhaled.

Product:
- Acute oral toxicity: Acute toxicity estimate: 1,031 mg/kg
  Method: Calculation method
- Acute inhalation toxicity: Acute toxicity estimate: 1.84 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: Calculation method
- Acute dermal toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method

Components:
Corn oil:
- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

N-Methyl-2-pyrrolidone:
- Acute oral toxicity: LD50 (Rat): 4,150 mg/kg
- Acute inhalation toxicity: LC50 (Rat): > 5.1 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: OECD Test Guideline 403
- Acute dermal toxicity: LD50 (Rat): > 5,000 mg/kg

Ivermectin:
- Acute oral toxicity: LD50 (Rat): 50 mg/kg
  LD50 (Mouse): 25 mg/kg
  LD50 (Monkey): > 24 mg/kg
  Target Organs: Central nervous system
  Symptoms: Vomiting, Dilatation of the pupil
  Remarks: No mortality observed at this dose.
- Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
  Exposure time: 1 h
## Test atmosphere

- Acute dermal toxicity: 
  - LD50 (Rabbit): 406 mg/kg
  - LD50 (Rat): > 660 mg/kg

### Abamectin (combination of avermectin B1a and avermectin B1b):

- **Acute oral toxicity**: 
  - LD50 (Rat): 24 mg/kg
  - LD50 (Mouse): 10 mg/kg
  - LDLo (Monkey): 24 mg/kg
  - Symptoms: Dilatation of the pupil

- **Acute inhalation toxicity**: 
  - LC50 (Rat): 0.023 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

- **Acute dermal toxicity**: 
  - LD50 (Rabbit): 330 mg/kg
  - LD50 (Rat): 2,000 mg/kg

### (dl)-a-Tocopheryl acetate:

- **Acute oral toxicity**: 
  - LD50 (Rat): > 5,000 mg/kg

- **Acute dermal toxicity**: 
  - LD50 (Rat): > 3,000 mg/kg
  - Assessment: The substance or mixture has no acute dermal toxicity

### Skin corrosion/irritation

- Causes skin irritation.

### Components:

#### N-Methyl-2-pyrrolidone:

- Result: Skin irritation

#### Ivermectin:

- **Species**: Rabbit
- **Result**: No skin irritation

#### Abamectin (combination of avermectin B1a and avermectin B1b):

- **Species**: Rabbit
- **Result**: No skin irritation

#### (dl)-a-Tocopheryl acetate:

- **Species**: Rabbit
- **Method**: OECD Test Guideline 404
- **Result**: No skin irritation
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version 5.0  Revision Date: 23.03.2020  SDS Number: 1209999-00010  Date of last issue: 13.09.2019  Date of first issue: 10.01.2017

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

N-Methyl-2-pyrrolidone:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Irritation to eyes, reversing within 21 days</td>
</tr>
</tbody>
</table>

Ivermectin:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

(dl)-a-Tocopheryl acetate:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No eye irritation</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 405</td>
</tr>
</tbody>
</table>

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Local lymph node assay (LLNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure routes</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 429</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Ivermectin:

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Dermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Humans</td>
</tr>
<tr>
<td>Result</td>
<td>Does not cause skin sensitisation.</td>
</tr>
</tbody>
</table>

Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximisation Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure routes</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>
(dl)-a-Tocopheryl acetate:
- **Test Type**: Draize Test
- **Exposure routes**: Skin contact
- **Species**: Humans
- **Result**: negative

**Chronic toxicity**

**Germ cell mutagenicity**
- Not classified based on available information.

**Components:**

**N-Methyl-2-pyrrolidone:**
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
  - **Method**: OECD Test Guideline 471
  - **Result**: negative
  - **Test Type**: In vitro mammalian cell gene mutation test
  - **Method**: OECD Test Guideline 476
  - **Result**: negative
  - **Test Type**: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - **Result**: negative

**Genotoxicity in vivo**
- **Test Type**: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - **Species**: Mouse
  - **Application Route**: Ingestion
  - **Method**: OECD Test Guideline 474
  - **Result**: negative
  - **Test Type**: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - **Species**: Hamster
  - **Application Route**: Ingestion
  - **Method**: OECD Test Guideline 475
  - **Result**: negative

**Ivermectin:**
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
  - **Result**: negative
  - **Test Type**: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - **Test system**: human diploid fibroblasts
  - **Result**: negative
  - **Test Type**: Mouse Lymphoma
  - **Result**: negative

**Abamectin (combination of avermectin B1a and avermectin B1b):**
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: Alkaline elution assay
  Result: negative

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  Species: Mouse
  Application Route: Intraperitoneal injection
  Result: negative

(dl)-a-Tocopheryl acetate:
- Genotoxicity in vitro:
  Test Type: Chromosome aberration test in vitro
  Method: OECD Test Guideline 473
  Result: negative

Carcinogenicity:
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 2 Years
- Result: negative

Ivermectin:
- Species: Rat
- Application Route: Oral
- NOAEL: 1.5 mg/kg body weight
- Result: negative
- Remarks: Based on data from similar materials
Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

(dl)-a-Tocopheryl acetate:
Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

N-Methyl-2-pyrrolidone:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Result: positive

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: positive

Reproductive toxicity - As: Clear evidence of adverse effects on development, based on
Assessment

Ivermectin:

Effects on fertility
: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development
: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Remarks: The mechanism or mode of action may not be relevant in humans.

Abamectin (combination of avermectin B1a and avermectin B1b):

Effects on fertility
: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity

Effects on foetal development
: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:
Effects on fertility: Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

STOT - single exposure
May cause respiratory irritation.
May cause damage to organs (Central nervous system) if swallowed.

Components:

N-Methyl-2-pyrrolidone:
Assessment: May cause respiratory irritation.

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT - repeated exposure
May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.
Abamectin (combination of avermectin B1a and avermectin B1b):

- **Exposure routes**: Ingestion
- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

**N-Methyl-2-pyrrolidone:**

- **Species**: Rat, male
- **NOAEL**: 169 mg/kg
- **LOAEL**: 433 mg/kg
- **Application Route**: Ingestion
- **Exposure time**: 90 Days
- **Method**: OECD Test Guideline 408

- **Species**: Rat
- **NOAEL**: 0.5 mg/l
- **LOAEL**: 1 mg/l
- **Application Route**: Inhalation (dust/mist/fume)
- **Exposure time**: 96 Days
- **Method**: OECD Test Guideline 413

- **Species**: Rabbit
- **NOAEL**: 826 mg/kg
- **LOAEL**: 1,653 mg/kg
- **Application Route**: Skin contact
- **Exposure time**: 20 Days

**Ivermectin:**

- **Species**: Dog
- **NOAEL**: 0.5 mg/kg
- **LOAEL**: 1 mg/kg
- **Application Route**: Oral
- **Exposure time**: 14 Weeks
- **Target Organs**: Central nervous system
- **Symptoms**: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

- **Species**: Monkey
- **NOAEL**: 1.2 mg/kg
- **Application Route**: Oral
- **Exposure time**: 2 Weeks
- **Remarks**: No significant adverse effects were reported

- **Species**: Rat
- **NOAEL**: 0.4 mg/kg
- **LOAEL**: 0.8 mg/kg
- **Application Route**: Oral
- **Exposure time**: 3 Months
- **Target Organs**: Spleen, Bone marrow, Kidney
Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>4.0 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, ataxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Tremors, weight loss</td>
</tr>
<tr>
<td>Remarks</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.0 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
</tbody>
</table>

(dl)-a-Tocopheryl acetate:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>500 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
</tbody>
</table>

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:

| Skin contact | Symptoms: Skin irritation |

Ivermectin:

| Skin contact | Remarks: Can be absorbed through skin. |
| Eye contact  | Remarks: May irritate eyes. |
| Ingestion    | Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination |

Abamectin (combination of avermectin B1a and avermectin B1b):
Ingestion: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Corn oil:

Toxicity to fish: LC0 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC0 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: EL50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Remarks: Based on data from similar materials

N-Methyl-2-pyrrolidone:

Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: DIN 38412

Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 12.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms: EC50: > 600 mg/l
Exposure time: 30 min
Method: ISO 8192

Ivermectin:

Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h
Toxicity to algae/aquatic plants:

- EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

Abamectin (combination of avermectin B1a and avermectin B1b):

- Toxicity to fish:
  - LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
    - Exposure time: 96 h
  - LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
    - Exposure time: 96 h
  - LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
    - Exposure time: 96 h
  - LC50 (Cyprinus carpio (Carp)): 42 µg/l
    - Exposure time: 96 h
  - LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
    - Exposure time: 96 h

- Toxicity to daphnia and other aquatic invertebrates:
  - EC50 (Americamysis): 0.022 µg/l
    - Exposure time: 96 h
  - EC50 (Daphnia magna (Water flea)): 0.34 µg/l
    - Exposure time: 48 h

- Toxicity to algae/aquatic plants:
  - EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
    - Exposure time: 72 h

- Toxicity to fish (Chronic toxicity):
  - NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
    - Exposure time: 32 d

- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
  - NOEC (Daphnia magna (Water flea)): 0.03 µg/l
    - Exposure time: 21 d
  - NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
    - Exposure time: 28 d

- Toxicity to microorganisms:
  - EC50: > 1,000 mg/l
    - Exposure time: 3 h
    - Test Type: Respiration inhibition

(dl)-a-Tocopherol acetate:

- Toxicity to fish:
  - LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
    - Exposure time: 96 h
    - Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
Exposure time: 28 d

Toxicity to microorganisms: EC50: > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Persistence and degradability

Components:

Corn oil:

Biodegradability: Result: Readily biodegradable.
Remarks: Based on data from similar materials

N-Methyl-2-pyrrolidone:

Biodegradability: Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin:

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

Abamectin (combination of avermectin B1a and avermectin B1b):

Stability in water: Hydrolysis: 50 % (< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 21.7 - 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301C
Bioaccumulative potential

Components:

Corn oil:
Partition coefficient: n-octanol/water: Remarks: No data available

N-Methyl-2-pyrrolidone:
Partition coefficient: n-octanol/water: log Pow: -0.46
Method: OECD Test Guideline 107

Ivermectin:
Bioaccumulation: Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water: log Pow: 3.22

Abamectin (combination of avermectin B1a and avermectin B1b):
Bioaccumulation: Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water: log Pow: 4

Mobility in soil

Components:

Abamectin (combination of avermectin B1a and avermectin B1b):
Distribution among environmental compartments: log Koc: > 3.6

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)
Class: 9
Packing group: III
## Ivermectin / Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0</td>
<td>23.03.2020</td>
<td>1209999-00010</td>
<td>13.09.2019</td>
<td>10.01.2017</td>
</tr>
</tbody>
</table>

### Labels

<table>
<thead>
<tr>
<th>IATA-DGR</th>
<th>UN/ID No.</th>
<th>Proper shipping name</th>
<th>Class</th>
<th>Packing group</th>
<th>Labels</th>
<th>Packing instruction (cargo aircraft)</th>
<th>Packing instruction (passenger aircraft)</th>
<th>Environmentally hazardous</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>UN 3082</td>
<td>Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)</td>
<td>9</td>
<td>III</td>
<td>Miscellaneous</td>
<td>964</td>
<td>yes</td>
<td></td>
</tr>
</tbody>
</table>

### IMDG-Code

<table>
<thead>
<tr>
<th>UN number</th>
<th>Proper shipping name</th>
<th>Class</th>
<th>Packing group</th>
<th>Labels</th>
<th>EmS Code</th>
<th>Marine pollutant</th>
</tr>
</thead>
<tbody>
<tr>
<td>UN 3082</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)</td>
<td>9</td>
<td>III</td>
<td>9</td>
<td>F-A, S-F</td>
<td>yes</td>
</tr>
</tbody>
</table>

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### ADG

<table>
<thead>
<tr>
<th>UN number</th>
<th>Proper shipping name</th>
<th>Class</th>
<th>Packing group</th>
<th>Labels</th>
<th>Hazchem Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>UN 3082</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)</td>
<td>9</td>
<td>III</td>
<td>9</td>
<td>•3Z</td>
</tr>
</tbody>
</table>

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

<table>
<thead>
<tr>
<th>Prohibition/Licensing Requirements</th>
<th>There is no applicable prohibition or</th>
</tr>
</thead>
</table>
The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

### SECTION 16. OTHER INFORMATION

**Further information**

- **Revision Date**: 23.03.2020

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

- **Date format**: dd.mm.yyyy
- **Full text of other abbreviations**

  - ACGIH BEI: ACGIH - Biological Exposure Indices (BEI)
  - AU OEL / TWA: Exposure standard - time weighted average
  - AU OEL / STEL: Exposure standard - short term exposure limit

  **AICS** - Australian Inventory of Chemical Substances; **ANTT** - National Agency for Transport by Land of Brazil; **ASTM** - American Society for the Testing of Materials; **bw** - Body weight; **CMR** - Carcinogen, Mutagen or Reproductive Toxicant; **DIN** - Standard of the German Institute for Standardisation; **DSL** - Domestic Substances List (Canada); **ECx** - Concentration associated with x% response; **ELx** - Loading rate associated with x% response; **EmS** - Emergency Schedule; **ENCx** - Existing and New Chemical Substances (Japan); **ErCx** - Concentration associated with x% growth rate response; **ERG** - Emergency Response Guide; **GHS** - Globally Harmonized System; **GLP** - Good Laboratory Practice; **IARC** - International Agency for Research on Cancer; **IATA** - International Air Transport Association; **IBC** - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; **IC50** - Half maximal inhibitory concentration; **ICAO** - International Civil Aviation Organization; **IECSC** - Inventory of Existing Chemical Substances in China; **IMDG** - International Maritime Dangerous Goods; **IMO** - International Maritime Organization; **ISHL** - Industrial Safety and Health Law (Japan); **ISO** - International Organisation for Standardization; **KECI** - Korea Existing Chemicals Inventory; **LC50** - Lethal Concentration to 50% of a test population; **LD50** - Lethal Dose to 50% of a test population (Median Lethal Dose); **MARPOL** - International Convention for the Prevention of Pollution from Ships; **n.o.s.** - Not Otherwise Specified; **Nch** - Chilean Norm; **NO(A)EC** - No Observed (Adverse) Effect Concentration; **NO(A)EL** - No Observed (Adverse) Effect Level; **NOELR** - No Observable Effect Loading Rate; **NOM** - Official Mexican Norm; **NTP** - National Toxicology Program; **NZIoC** - New Zealand Inventory of Chemicals; **OECD** - Organization for Economic Co-operation and Develop-
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.